TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568): Valuation Update After Enhertu’s Health Canada Approval Expands Market Potential
Daiichi Sankyo (TSE:4568) shares drew attention after the company, together with AstraZeneca Canada, secured Health Canada's approval for Enhertu as a treatment for specific advanced breast cancer types. This approval followed strong phase III trial results.
See our latest analysis for Daiichi Sankyo Company.
This pivotal news comes after a difficult stretch for Daiichi Sankyo’s stock, which has seen its share price drop over 20% year-to-date and a one-year total shareholder return of -28.5%...